Safety and Efficacy of TP10, a Complement Inhibitor, in Adult Women Undergoing Cardiopulmonary Bypass Surgery
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the study drug (TP10), which blocks complement
release, can reduce such side effects of complement inflammation as chest pain or heart
attacks and be taken safely in women who undergo cardiopulmonary bypass surgery.